PSNL
NASDAQ · Life Sciences Tools & Services
Personalis Inc
$7.68
+0.42 (+5.79%)
Financial Highlights (FY 2026)
Revenue
139.33M
Net Income
-133,848,513
Gross Margin
31.7%
Profit Margin
-96.1%
Rev Growth
-0.3%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 31.7% | 31.7% | 34.5% | 34.5% |
| Operating Margin | -80.7% | -72.6% | 8.7% | 7.6% |
| Profit Margin | -96.1% | -91.3% | 7.4% | 5.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 139.33M | 139.81M | 842.44M | 788.11M |
| Gross Profit | 44.17M | 44.32M | 290.48M | 271.75M |
| Operating Income | -112,412,758 | -101,516,638 | 73.02M | 60.07M |
| Net Income | -133,848,513 | -120,874,635 | 62.65M | 45.28M |
| Gross Margin | 31.7% | 31.7% | 34.5% | 34.5% |
| Operating Margin | -80.7% | -72.6% | 8.7% | 7.6% |
| Profit Margin | -96.1% | -91.3% | 7.4% | 5.8% |
| Rev Growth | -0.3% | -0.3% | +3.3% | +14.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.41M | 3.41M | 109.54M | 111.95M |
| Total Equity | 392.21M | 392.21M | 454.92M | 451.32M |
| D/E Ratio | 0.01 | 0.01 | 0.24 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -124,833,568 | -118,996,477 | 87.86M | 84.18M |
| Free Cash Flow | — | — | 62.43M | 43.12M |